FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Pepys

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Concepts & Ideas

Physiology

Mutation

Anatomy

Co-author Network

Publications

TOP 3
Adrienne E Campbell-Washburn; Stephan Ellmerich; Rupinder Ghatrora; Philip N Hawkins; Tammy L Kalber; James C Moon; Roger J Ordidge; Mark B Pepys; Anthony N Price; J Paul Simons; Raya Al-Shawi; Mark F Lythgoe
Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction.
Reecha Sofat; Nick Wareham; Francesco D'Aiuto; J Ruth Gallimore; Tim Goodship; Svetlana Hakobyan; Timothy R Hughes; Claudia Langenberg; P Patrizia Mangione; B Paul Morgan; Mark B Pepys; Tina Shah; Aroon D Hingorani
Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay.
Mark B Pepys
Invasive candidiasis: new insights presaging new therapeutic approaches?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Pepys (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Adrienne E Campbell-Washburn; Stephan Ellmerich; Rupinder Ghatrora; Philip N Hawkins; Tammy L Kalber; James C Moon; Roger J Ordidge; Mark B Pepys; Anthony N Price; J Paul Simons; Raya Al-Shawi; Mark F Lythgoe
Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2013;20(2):93-8.
2013: Reecha Sofat; Nick Wareham; Francesco D'Aiuto; J Ruth Gallimore; Tim Goodship; Svetlana Hakobyan; Timothy R Hughes; Claudia Langenberg; P Patrizia Mangione; B Paul Morgan; Mark B Pepys; Tina Shah; Aroon D Hingorani
Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay.
Journal of immunological methods 2013;390(1-2):63-73.
2012: Mark B Pepys
Invasive candidiasis: new insights presaging new therapeutic approaches?
The Journal of infectious diseases 2012;206(9):1339-41.
2012: Mark B Pepys; Stephen Poole; Graham W Taylor; Glenys A Tennent; Gary Bennett; Stephan Ellmerich; David Evans; J Ruth Gallimore; David Graham; Winston L Hutchinson; Zhanhong Li; Joanne Lloyd; Palma P Mangione; David J Millar; Yogesh Mistry; John More; Philip N Hawkins
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.
Journal of immunological methods 2012;384(1-2):92-102.
2010: Simon Kolstoe; Palma P Mangione; Vittorio Bellotti; Graham W Taylor; Glenys A Tennent; Stéphanie Deroo; Angus J Morrison; Alexander Cobb; Anthony Coyne; Margaret G McCammon; Timothy D Warner; Jane Mitchell; Raj Gill; Martin D Smith; Steven V Ley; Carol V Robinson; Steve P Wood; Mark B Pepys
Trapping of palindromic ligands within native transthyretin prevents amyloid formation.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(47):20483-8.
2010: Karl Bodin; Stephan Ellmerich; Melvyn C Kahan; Glenys A Tennent; Andrzej Loesch; Janet A Gilbertson; Winston L Hutchinson; Palma P Mangione; J Ruth Gallimore; David J Millar; Shane Minogue; Amar P Dhillon; Graham W Taylor; Arthur R Bradwell; Aviva Petrie; Julian D Gillmore; Vittorio Bellotti; Marina Botto; Philip N Hawkins; Mark B Pepys
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
Nature 2010;468(7320):93-7.
2010: Julian D Gillmore; Glenys A Tennent; Winston L Hutchinson; J Ruth Gallimore; Helen J Lachmann; Hugh J B Goodman; Mark Offer; David J Millar; Aviva Petrie; Philip N Hawkins; Mark B Pepys
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
British journal of haematology 2010;148(5):760-7.
2010: Stephen Kaptoge; Emanuele Di Angelantonio; Gordon Lowe; Mark B Pepys; Simon G Thompson; Rory Collins; John Danesh
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
Lancet 2010;375(9709):132-40.
2009: Simon Kolstoe; Basil H Ridha; Vittorio Bellotti; Nan Wang; Carol V Robinson; Sebastian J Crutch; Geoffrey Keir; Riitta Kukkastenvehmas; J Ruth Gallimore; Winston L Hutchinson; Philip N Hawkins; Steve P Wood; Martin N Rossor; Mark B Pepys
Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(18):7619-23.
2009: Mark B Pepys
Jack Pepys (May 15, 1914-September 9, 1996): a personal recollection.
The Journal of allergy and clinical immunology 2009;123(3):718-20.
2008: Svetlana Hakobyan; Claire L Harris; Carmen W van den Berg; Maria Carmen Fernandez-Alonso; Elena Goicoechea de Jorge; Santiago Rodriguez de Cordoba; German Rivas; Palma Mangione; Mark B Pepys; B Paul Morgan
Complement factor H binds to denatured rather than to native pentameric C-reactive protein.
The Journal of biological chemistry 2008;283(45):30451-60.
2008: Mark B Pepys
C-reactive protein is neither a marker nor a mediator of atherosclerosis.
Nature clinical practice. Nephrology 2008;4(5):234-5.
2008: Glenys A Tennent; Winston L Hutchinson; Melvyn C Kahan; Gideon M Hirschfield; J Ruth Gallimore; Jackie Lewin; Caroline A Sabin; Amar P Dhillon; Mark B Pepys
Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice.
Atherosclerosis 2008;196(1):248-55.
2007: Mark B Pepys
Science and serendipity.
Clinical medicine (London, England) 2007;7(6):562-78.
2007: Glenys A Tennent; Mark W Head; Matthew Bishop; Philip N Hawkins; Robert G Will; R Knight; Alexander H Peden; Linda McCardle; James W Ironside; Mark B Pepys
Disease-associated prion protein is not detectable in human systemic amyloid deposits.
The Journal of pathology 2007;213(4):376-83.
2007: Glenys A Tennent; Magdalena Dziadzio; Eva Triantafillidou; Phillip Davies; J Ruth Gallimore; Christopher P Denton; Mark B Pepys
Normal circulating serum amyloid P component concentration in systemic sclerosis.
Arthritis and rheumatism 2007;56(6):2013-7.
2007: Leo C James; Phil C Jones; Airlie McCoy; Glenys A Tennent; Mark B Pepys; Kristoffer Famm; Greg Winter
Beta-edge interactions in a pentadecameric human antibody V kappa domain.
Journal of molecular biology 2007;367(3):603-8.
2007: Glenys A Tennent; Stephen O Brennan; Arie J Stangou; John O'Grady; Philip N Hawkins; Mark B Pepys
Human plasma fibrinogen is synthesized in the liver.
Blood 2007;109(5):1971-4.
2007: Winston L Hutchinson; Anthony P Coll; J Ruth Gallimore; Glenys A Tennent; Mark B Pepys
Is leptin an important physiological regulator of CRP?
Nature medicine 2007;13(1):17-8; author reply 19-21.
2006: Julian D Gillmore; Arie J Stangou; Helen J Lachmann; Hugh J B Goodman; Ashutosh D Wechalekar; J Acheson; Glenys A Tennent; Alison Bybee; Janet A Gilbertson; Dorota M Rowczenio; John O'Grady; ND Heaton; Mark B Pepys; Philip N Hawkins
Organ transplantation in hereditary apolipoprotein AI amyloidosis.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006;6(10):2342-7.
2006: Gordon D O Lowe; Mark B Pepys
C-reactive protein and cardiovascular disease: weighing the evidence.
Current atherosclerosis reports 2006;8(5):421-8.
2006: Mark B Pepys; Gideon M Hirschfield; Glenys A Tennent; J Ruth Gallimore; Melvyn C Kahan; Vittorio Bellotti; Philip N Hawkins; Rebecca M Myers; Martin D Smith; Alessandra Polara; Alexander Cobb; Steven V Ley; J Andrew Aquilina; Carol V Robinson; Isam Sharif; Gillian A Gray; Caroline A Sabin; Michelle C Jenvey; Simon Kolstoe; Darren Thompson; Steve P Wood
Targeting C-reactive protein for the treatment of cardiovascular disease.
Nature 2006;440(7088):1217-21.
2006: Glen D Armstrong; George L Mulvey; Paola Marcato; Thomas P Griener; Melvyn C Kahan; Glenys A Tennent; Caroline A Sabin; Henrik Chart; Mark B Pepys
Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome.
The Journal of infectious diseases 2006;193(8):1120-4.
2006: Julian D Gillmore; Hugh J B Goodman; Helen J Lachmann; Mark Offer; Ashutosh D Wechalekar; Jayshree Joshi; Mark B Pepys; Philip N Hawkins
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.
Blood 2006;107(3):1227-9.
2006: Mark B Pepys
Amyloidosis.
Annual review of medicine 2006;57():223-41.
2005: Mark B Pepys; Philip N Hawkins; Melvyn C Kahan; Glenys A Tennent; J Ruth Gallimore; David Graham; Caroline A Sabin; Arturo Zychlinsky; Juana de Diego
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself.
Circulation research 2005;97(11):e97-103.
2005: Gideon M Hirschfield; J Ruth Gallimore; Melvyn C Kahan; Winston L Hutchinson; Caroline A Sabin; Gregory Martin Benson; Amar P Dhillon; Glenys A Tennent; Mark B Pepys
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(23):8309-14.
2005: Mark B Pepys
CRP or not CRP? That is the question.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(6):1091-4.
2005: M Noursadeghi; Mark B Pepys; Ruth Gallimore; J Cohen
Relationship of granulocyte colony stimulating factor with other acute phase reactants in man.
Clinical and experimental immunology 2005;140(1):97-100.
2005: Brian R Clapp; Gideon M Hirschfield; Clare Storry; J Ruth Gallimore; Ray Stidwill; Mervyn Singer; John E Deanfield; Raymond J MacAllister; Mark B Pepys; Patrick Vallance; Aroon D Hingorani
Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability.
Circulation 2005;111(12):1530-6.
2004: Ramanjit Gill; John A Kemp; Caroline Sabin; Mark B Pepys
Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2004;24(11):1214-8.
2004: Jerry R Greenfield; Katherine Samaras; Arthur B Jenkins; Paul J Kelly; Tim D Spector; J Ruth Gallimore; Mark B Pepys; Lesley V Campbell
Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences.
Circulation 2004;109(24):3022-8.
2004: Abuzeid H Gomma; Gideon M Hirschfield; J Ruth Gallimore; Gordon D O Lowe; Mark B Pepys; Kim M Fox
Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting.
American heart journal 2004;147(6):1071-7.
2004: Julian D Gillmore; Winston L Hutchinson; Jeff Herbert; Alison Bybee; Daniel A Mitchell; Robert P Hasserjian; Ken-Ichi Yamamura; Misao Suzuki; Caroline A Sabin; Mark B Pepys
Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?
Immunology 2004;112(2):255-64.
2004: Winston L Hutchinson; Jeff Herbert; Marina Botto; Mark B Pepys
Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.
Immunology 2004;112(2):250-4.
2004: John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
The New England journal of medicine 2004;350(14):1387-97.
2004: Alex J MacGregor; J Ruth Gallimore; Tim D Spector; Mark B Pepys
Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins.
Clinical chemistry 2004;50(1):130-4.
2003: Gideon M Hirschfield; Jeff Herbert; Melvyn C Kahan; Mark B Pepys
Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(11):6046-51.
2003: Gideon M Hirschfield; Mark B Pepys
C-reactive protein and cardiovascular disease: new insights from an old molecule.
QJM : monthly journal of the Association of Physicians 2003;96(11):793-807.
2003: Natalie Khuseyinova; Armin Imhof; Gerlinde Trischler; Dietrich Rothenbacher; Winston L Hutchinson; Mark B Pepys; Wolfgang Koenig
Determination of C-reactive protein: comparison of three high-sensitivity immunoassays.
Clinical chemistry 2003;49(10):1691-5.
2003: Wolfgang Koenig; Malte Sund; Margit Fröhlich; Hannelore Löwel; Winston L Hutchinson; Mark B Pepys
Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987.
American journal of epidemiology 2003;158(4):357-64.
2003: Helen J Lachmann; Ruth Gallimore; Julian D Gillmore; Hugh D Carr-Smith; Arthur R Bradwell; Mark B Pepys; Philip N Hawkins
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
British journal of haematology 2003;122(1):78-84.
2003: Mark B Pepys; Gideon M Hirschfield
C-reactive protein: a critical update.
The Journal of clinical investigation 2003;111(12):1805-12.
2003: Mark B Pepys; Alison Bybee; David R Booth; Matthew Bishop; Robert G Will; Ann-Margaret Little; Bedrich Prokupek; J Alejandro Madrigal
MHC typing in variant Creutzfeldt-Jakob disease.
Lancet 2003;361(9356):487-9.
2003: Margit Fröhlich; Nikolai Mühlberger; Hartmut Hanke; Armin Imhof; Angela Döring; Mark B Pepys; Wolfgang Koenig
Markers of inflammation in women on different hormone replacement therapies.
Annals of medicine 2003;35(5):353-61.
2002: Mahdad Noursadeghi; Maria C M Bickerstaff; Jeff Herbert; David Moyes; Jonathan Cohen; Mark B Pepys
Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(2):913-9.
2002: Helen J Lachmann; David R Booth; Susanne E Booth; Alison Bybee; Janet A Gilbertson; Julian D Gillmore; Mark B Pepys; Philip N Hawkins
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
The New England journal of medicine 2002;346(23):1786-91.
2002: Mark B Pepys; Jeff Herbert; Winston L Hutchinson; Glenys A Tennent; Helen J Lachmann; J Ruth Gallimore; Laurence Bruce Lovat; T Bartfai; Alexander Alanine; C Hertel; T Hoffmann; Roland Jakob-Roetne; R D Norcross; J A Kemp; Ken-Ichi Yamamura; Misao Suzuki; G W Taylor; S Murray; D Thompson; A Purvis; Simon Kolstoe; Steve P Wood; Philip N Hawkins
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Nature 2002;417(6886):254-9.
2002: Wolfgang Koenig; Mark B Pepys
C-reactive protein risk prediction: low specificity, high sensitivity.
Annals of internal medicine 2002;136(7):550-2.
2002: Helen J Lachmann; Janet A Gilbertson; Julian D Gillmore; Philip N Hawkins; Mark B Pepys
Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease.
QJM : monthly journal of the Association of Physicians 2002;95(4):211-8.
2002: Margit Fröhlich; Malte Sund; Barbara Thorand; Winston L Hutchinson; Mark B Pepys; Wolfgang Koenig
Lack of seasonal variation in C-reactive protein.
Clinical chemistry 2002;48(3):575-7.
2002: Jeff Herbert; Winston L Hutchinson; Jackie Carr; Jane Ives; Roland Jakob-Roetne; Ken-Ichi Yamamura; Misao Suzuki; Mark B Pepys
Influenza virus infection is not affected by serum amyloid P component.
Molecular medicine (Cambridge, Mass.) 2002;8(1):9-15.
2001: Mark B Pepys; Gideon M Hirschfield
C-reactive protein and its role in the pathogenesis of myocardial infarction.
Italian heart journal : official journal of the Italian Federation of Cardiology 2001;2(11):804-6.
2001: José L Jiménez; G Tennent; Mark B Pepys; Helen R Saibil
Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy.
Journal of molecular biology 2001;311(2):241-7.
2001: Julian D Gillmore; Laurence Bruce Lovat; MR Persey; Mark B Pepys; Philip N Hawkins
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
Lancet 2001;358(9275):24-9.
2001: Armin Imhof; M Froehlich; Hermann Brenner; H Boeing; Mark B Pepys; Wolfgang Koenig
Effect of alcohol consumption on systemic markers of inflammation.
Lancet 2001;357(9258):763-7.
2001: Mark B Pepys; Gideon M Hirschfield
C-reactive protein and atherothrombosis.
Italian heart journal : official journal of the Italian Federation of Cardiology 2001;2(3):196-9.
2001: Mark B Pepys
Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2001;356(1406):203-10; discussion 210-1.
2000: Mahdad Noursadeghi; Maria C M Bickerstaff; J Ruth Gallimore; Jeff Herbert; Jonathan Cohen; Mark B Pepys
Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(26):14584-9.
2000: Margit Fröhlich; Armin Imhof; G Berg; Winston L Hutchinson; Mark B Pepys; H Boeing; Rainer Muche; H Brenner; Wolfgang Koenig
Association between C-reactive protein and features of the metabolic syndrome: a population-based study.
Diabetes care 2000;23(12):1835-9.
2000: Julian D Gillmore; S Madhoo; Mark B Pepys; Philip N Hawkins
Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy.
Nuclear medicine communications 2000;21(8):735-40.
2000: David R Booth; Mark B Pepys; Philip N Hawkins
A novel variant of human lysozyme (T70N) is common in the normal population.
Human mutation 2000;16(2):180.
2000: Louise C Serpell; Margaret Sunde; M D Benson; G A Tennent; Mark B Pepys; Paul E Fraser
The protofilament substructure of amyloid fibrils.
Journal of molecular biology 2000;300(5):1033-9.
2000: Winston L Hutchinson; Wolfgang Koenig; Margit Fröhlich; Malte Sund; Gordon D O Lowe; Mark B Pepys
Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population.
Clinical chemistry 2000;46(7):934-8.
2000: Winston L Hutchinson; E Hohenester; Mark B Pepys
Human serum amyloid P component is a single uncomplexed pentamer in whole serum.
Molecular medicine (Cambridge, Mass.) 2000;6(6):482-93.
2000: Julian D Gillmore; David R Booth; M Rela; ND Heaton; V Rahman; Arie J Stangou; Mark B Pepys; Philip N Hawkins
Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family.
QJM : monthly journal of the Association of Physicians 2000;93(5):269-75.
2000: David R Booth; Julian D Gillmore; Helen J Lachmann; Susanne E Booth; Alison Bybee; Müjde Soytürk; Servet Akar; Mark B Pepys; Mehmet Tunca; Philip N Hawkins
The genetic basis of autosomal dominant familial Mediterranean fever.
QJM : monthly journal of the Association of Physicians 2000;93(4):217-21.
1999: M Griselli; Jeff Herbert; Winston L Hutchinson; K M Taylor; M Sohail; Thomas Krausz; Mark B Pepys
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.
The Journal of experimental medicine 1999;190(12):1733-40.
1999: Wolfgang Koenig; Dietrich Rothenbacher; Albrecht Hoffmeister; M Miller; Guenter Bode; G Adler; Vinzenz Hombach; Winfried März; Mark B Pepys; Hermann Brenner
Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response.
Circulation 1999;100(23):2326-31.
1999: Julian D Gillmore; David R Booth; S Madhoo; Mark B Pepys; Philip N Hawkins
Hereditary renal amyloidosis associated with variant lysozyme in a large English family.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14(11):2639-44.
1999: Julian D Gillmore; David R Booth; Mark B Pepys; Philip N Hawkins
Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man.
Heart (British Cardiac Society) 1999;82(3):e2.
1999: S Y Tan; R Baillod; E Brown; K Farrington; C Soper; M Percy; Elaine J Clutterbuck; S Madhoo; Mark B Pepys; Philip N Hawkins
Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14(6):1467-71.
1999: Maria C M Bickerstaff; Marina Botto; Winston L Hutchinson; Jeff Herbert; Glenys A Tennent; Alison Bybee; D A Mitchell; H T Cook; P J Butler; Mark J Walport; Mark B Pepys
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity.
Nature medicine 1999;5(6):694-7.
1999: Mehmet Tunca; Guldal KIRKALI; Müjde Soytürk; Servet Akar; Mark B Pepys; Philip N Hawkins
Acute phase response and evolution of familial Mediterranean fever.
Lancet 1999;353(9162):1415.
1999: M Brett; MR Persey; M M Reilly; Tamas Revesz; David R Booth; Susanne E Booth; Philip N Hawkins; Mark B Pepys; J A Morgan-Hughes
Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis.
Brain : a journal of neurology 1999;122 ( Pt 2)():183-90.
1999: Wolfgang Koenig; Malte Sund; Margit Fröhlich; HG Fischer; Hannelore Löwel; Angela Döring; Winston L Hutchinson; Mark B Pepys
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
Circulation 1999;99(2):237-42.
1998: David R Booth; Susanne E Booth; Julian D Gillmore; Philip N Hawkins; Mark B Pepys
SAA1 alleles as risk factors in reactive systemic AA amyloidosis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 1998;5(4):262-5.
1998: David R Booth; Julian D Gillmore; Susanne E Booth; Mark B Pepys; Philip N Hawkins
Pyrin/marenostrin mutations in familial Mediterranean fever.
QJM : monthly journal of the Association of Physicians 1998;91(9):603-6.
1998: Laurence Bruce Lovat; A A O'Brien; S F Armstrong; S Madhoo; C J Bulpitt; Martin N Rossor; Mark B Pepys; Philip N Hawkins
Scintigraphy with 123I-serum amyloid P component in Alzheimer disease.
Alzheimer disease and associated disorders 1998;12(3):208-10.
1998: Arie J Stangou; Philip N Hawkins; ND Heaton; M Rela; M Monaghan; P Nihoyannopoulos; John O'Grady; Mark B Pepys; R Williams
Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis.
Transplantation 1998;66(2):229-33.
1998: Philip N Hawkins; C Aprile; Giuseppe Capri; Lucia Viganò; Elisabetta Munzone; Luca Gianni; Mark B Pepys; G Merlini
Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis.
European journal of nuclear medicine 1998;25(7):701-8.
1998: Arie J Stangou; ND Heaton; M Rela; Mark B Pepys; Philip N Hawkins; R Williams
Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy.
Transplantation 1998;65(11):1496-8.
1998: J Wilkins; J R Gallimore; E G Moore; Mark B Pepys
Rapid automated high sensitivity enzyme immunoassay of C-reactive protein.
Clinical chemistry 1998;44(6 Pt 1):1358-61.
1998: Laurence Bruce Lovat; MR Persey; S Madhoo; Mark B Pepys; Philip N Hawkins
The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.
Gut 1998;42(5):727-34.
1998: MR Persey; David R Booth; Susanne E Booth; R van Zyl-Smit; B K Adams; A B Fattaar; Glenys A Tennent; Philip N Hawkins; Mark B Pepys
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I.
Kidney international 1998;53(2):276-81.
1997: J D Gillmore; Philip N Hawkins; Mark B Pepys
Amyloidosis: a review of recent diagnostic and therapeutic developments.
British journal of haematology 1997;99(2):245-56.
1997: Margaret Sunde; Louise C Serpell; Mark Bartlam; Paul E Fraser; Mark B Pepys; CC Blake
Common core structure of amyloid fibrils by synchrotron X-ray diffraction.
Journal of molecular biology 1997;273(3):729-39.
1997: G J Clesham; David M Vigushin; Philip N Hawkins; Mark B Pepys; C M Oakley; Petros Nihoyannopoulos
Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance.
The American journal of cardiology 1997;80(8):1104-8.
1997: AW Ashton; Mark K Boehm; J R Gallimore; Mark B Pepys; Stephen J Perkins
Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses.
Journal of molecular biology 1997;272(3):408-22.
1997: Marina Botto; Philip N Hawkins; Maria C M Bickerstaff; Jeff Herbert; Anne Elisabeth Bygrave; A McBride; Winston L Hutchinson; Glenys A Tennent; Mark J Walport; Mark B Pepys
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene.
Nature medicine 1997;3(8):855-9.
1997: E Hohenester; Winston L Hutchinson; Mark B Pepys; Steve P Wood
Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP.
Journal of molecular biology 1997;269(4):570-8.
1997: Laurence Bruce Lovat; Mark B Pepys; Philip N Hawkins
Amyloid and the gut.
Digestive diseases (Basel, Switzerland) 1997;15(3):155-71.
1997: Laurence Bruce Lovat; S Madhoo; Mark B Pepys; Philip N Hawkins
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease.
Gastroenterology 1997;112(4):1362-5.
1997: MB Hogarth; Ruth Gallimore; P Savage; A J Palmer; J M Starr; Christopher J Bulpitt; Mark B Pepys
Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient.
Age and ageing 1997;26(2):153-8.
1997: David R Booth; M Sunde; Vittorio Bellotti; C V Robinson; Winston L Hutchinson; Paul E Fraser; Philip N Hawkins; C M Dobson; S E Radford; CC Blake; Mark B Pepys
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis.
Nature 1997;385(6619):787-93.
1996: Ian Elliot Murdoch; T J Sullivan; I Moseley; Philip N Hawkins; Mark B Pepys; S Y Tan; A Garner; JE Wright
Primary localised amyloidosis of the orbit.
The British journal of ophthalmology 1996;80(12):1083-6.
1996: S Y Tan; A Irish; C G Winearls; E A Brown; P E Gower; Elaine J Clutterbuck; S Madhoo; J P Lavender; Mark B Pepys; Philip N Hawkins
Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology.
Kidney international 1996;50(1):282-9.
1996: David R Booth; S Y Tan; Susanne E Booth; Glenys A Tennent; Winston L Hutchinson; J Justin Hsuan; Nick Totty; O Truong; Anne K Soutar; Philip N Hawkins; M Bruguera; J Caballería; M Solé; J M Campistol; Mark B Pepys
Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.
The Journal of clinical investigation 1996;97(12):2714-21.
1996: Mark B Pepys; Glenys A Tennent; David R Booth; Vittorio Bellotti; Laurence Bruce Lovat; S Y Tan; MR Persey; Winston L Hutchinson; Susanne E Booth; S Madhoo; Anne K Soutar; Philip N Hawkins; R Van Zyl-Smit; J M Campistol; Paul E Fraser; S E Radford; Carol V Robinson; Margaret Sunde; Louise C Serpell; CC Blake
Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.
Ciba Foundation symposium 1996;199():73-81; discussion 81-9.
1995: M M Reilly; david adams; David R Booth; Mary B Davis; Gérard Said; M Laubriat-Bianchin; Mark B Pepys; PK Thomas; AE Harding
Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy.
Brain : a journal of neurology 1995;118 ( Pt 4)():849-56.
1995: Glenys A Tennent; Laurence Bruce Lovat; Mark B Pepys
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(10):4299-303.
1995: David R Booth; S Y Tan; Philip N Hawkins; Mark B Pepys; A Frustaci
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family.
Circulation 1995;91(4):962-7.
1994: S Y Tan; Ian Elliot Murdoch; T J Sullivan; JE Wright; O Truong; J Justin Hsuan; Philip N Hawkins; Mark B Pepys
Primary localized orbital amyloidosis composed of the immunoglobulin gamma heavy chain CH3 domain.
Clinical science (London, England : 1979) 1994;87(5):487-91.
1994: S Y Tan; Mark B Pepys
Amyloidosis.
Histopathology 1994;25(5):403-14.
1994: Winston L Hutchinson; G E Noble; Philip N Hawkins; Mark B Pepys
The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.
The Journal of clinical investigation 1994;94(4):1390-6.
1994: Mark B Pepys; Susanne E Booth; Glenys A Tennent; P J Butler; david williams
Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli.
Clinical and experimental immunology 1994;97(1):152-7.
1994: J Wilkins; J R Gallimore; Glenys A Tennent; Philip N Hawkins; P C Limburg; M H van Rijswijk; E G Moore; Mark B Pepys
Rapid automated enzyme immunoassay of serum amyloid A.
Clinical chemistry 1994;40(7 Pt 1):1284-90.
1994: Philip N Hawkins; Martin N Rossor; J R Gallimore; B Miller; E G Moore; Mark B Pepys
Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.
Biochemical and biophysical research communications 1994;201(2):722-6.
1994: Mark B Pepys; T W Rademacher; S Amatayakul-Chantler; P Williams; G E Noble; Winston L Hutchinson; Philip N Hawkins; S R Nelson; J R Gallimore; Jeff Herbert
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(12):5602-6.
1994: D M Vigushin; Philip N Hawkins; J Justin Hsuan; Nick Totty; Mark B Pepys
AL kappa amyloid in a solitary extradural lymphoma.
Journal of neurology, neurosurgery, and psychiatry 1994;57(6):751-4.
1994: Glenys A Tennent; Mark B Pepys
Glycobiology of the pentraxins.
Biochemical Society transactions 1994;22(1):74-9.
1993: Glenys A Tennent; M L Baltz; G D Osborn; P J Butler; G E Noble; Philip N Hawkins; Mark B Pepys
Studies of the structure and binding properties of hamster female protein.
Immunology 1993;80(4):645-51.
1993: Philip N Hawkins; S Richardson; D M Vigushin; J David; C R Kelsey; R E Gray; M A Hall; P Woo; J P Lavender; Mark B Pepys
Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis.
Arthritis and rheumatism 1993;36(6):842-51.
1993: Philip N Hawkins; S Richardson; J E MacSweeney; A D King; D M Vigushin; J P Lavender; Mark B Pepys
Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression.
The Quarterly journal of medicine 1993;86(6):365-74.
1993: Mark B Pepys
Rheumatoid arthritis: the role of acute-phase proteins.
British journal of rheumatology 1993;32 Suppl 3():1-2.
1993: Mark B Pepys; Philip N Hawkins; David R Booth; D M Vigushin; Glenys A Tennent; Anne K Soutar; Nick Totty; O Nguyen; CC Blake; C J Terry
Human lysozyme gene mutations cause hereditary systemic amyloidosis.
Nature 1993;362(6420):553-7.
1993: D M Vigushin; Mark B Pepys; Philip N Hawkins
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.
The Journal of clinical investigation 1993;91(4):1351-7.
1993: A F Bristow; Rose E Gaines Das; N Buttress; J R Gallimore; Glenys A Tennent; Mark B Pepys
The International Standard for Thyroxine Binding Globulin.
Clinical endocrinology 1993;38(4):361-6.
1992: Mark B Pepys
Amyloid P component and the diagnosis of amyloidosis.
Journal of internal medicine 1992;232(6):519-21.
1991: S R Nelson; Glenys A Tennent; D Sethi; P E Gower; F W Ballardie; S Amatayakul-Chantler; Mark B Pepys
Serum amyloid P component in chronic renal failure and dialysis.
Clinica chimica acta; international journal of clinical chemistry 1991;200(2-3):191-9.
1991: S R Nelson; Philip N Hawkins; S Richardson; J P Lavender; D Sethi; P E Gower; C W Pugh; C G Winearls; D O Oliver; Mark B Pepys
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component.
Lancet 1991;338(8763):335-9.
1991: Philip N Hawkins; Glenys A Tennent; P Woo; Mark B Pepys
Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.
Clinical and experimental immunology 1991;84(2):308-16.
1991: S R Nelson; M Lyon; J T Gallagher; E A Johnson; Mark B Pepys
Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils.
The Biochemical journal 1991;275 ( Pt 1)():67-73.
1990: Philip N Hawkins; R Wootton; Mark B Pepys
Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.
The Journal of clinical investigation 1990;86(6):1862-9.
1990: Philip N Hawkins; J P Lavender; Mark B Pepys
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
The New England journal of medicine 1990;323(8):508-13.
1990: Philip N Hawkins; Mark B Pepys
A primed state exists in vivo following histological regression of amyloidosis.
Clinical and experimental immunology 1990;81(2):325-8.
1990: P J Butler; Glenys A Tennent; Mark B Pepys
Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin.
The Journal of experimental medicine 1990;172(1):13-8.
1990: S R Nelson; Mark B Pepys
Preparative isolation of human beta 2-microglobulin from urine.
Journal of immunological methods 1990;128(2):277-80.
1989: S Levi; C T Dollery; Stephen R Bloom; J Calam; T M Cox; Humphrey Hodgson; M S Losowsky; Mark B Pepys; N A Wright; O M Wrong
Campylobacter pylori, duodenal ulcer disease, and gastrin.
BMJ (Clinical research ed.) 1989;299(6707):1093-4.
1989: P Hawkins; Stephen R Bloom; J Cassar; T M Cox; Mark B Pepys; J Waxman
Imaging amyloidosis in Still's disease.
BMJ (Clinical research ed.) 1989;299(6703):848-50.
1989: Mark B Pepys; M L Baltz; Glenys A Tennent; J Kent; J Ousey; P D Rossdale
Serum amyloid A protein (SAA) in horses: objective measurement of the acute phase response.
Equine veterinary journal 1989;21(2):106-9.
1988: Philip N Hawkins; M J Myers; J P Lavender; Mark B Pepys
Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.
Lancet 1988;1(8600):1413-8.
1988: Mark B Pepys
Amyloidosis: some recent developments.
The Quarterly journal of medicine 1988;67(252):283-98.
1988: Philip N Hawkins; M J Myers; A A Epenetos; D Caspi; Mark B Pepys
Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component.
The Journal of experimental medicine 1988;167(3):903-13.
1987: Mark B Pepys; P J Butler
Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum.
Biochemical and biophysical research communications 1987;148(1):308-13.
1987: Stuart Maudsley; Mark B Pepys
Immunochemical cross-reactions between pentraxins of different species.
Immunology 1987;62(1):17-22.
1982: C Rordorf; H P Schnebli; M L Baltz; Glenys A Tennent; Mark B Pepys
The acute-phase response in (NZB X NZW)F1 and MRL/l MICE.
The Journal of experimental medicine 1982;156(4):1268-73.